Cited by 213Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsAdvanced MRI Techniques and Applications

The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer’s Disease

Open access
Hays, Chelsea C., Zlatar, Zvinka Z., Wierenga, Christina E.·2016·Cellular and Molecular Neurobiology

Abstract

There is accumulating evidence suggesting that changes in brain perfusion are present long before the clinical symptoms of Alzheimer's disease (AD), perhaps even before amyloid-β accumulation or brain atrophy. This evidence, consistent with the vascular hypothesis of AD, implicates cerebral blood flow (CBF) in the pathogenesis of AD and suggests its utility as a biomarker of preclinical AD. The extended preclinical phase of AD holds particular significance for disease modification, as treatment would likely be most effective in this early asymptomatic stage of disease. This highlights the importance of identifying reliable and accurate biomarkers of AD that can differentiate normal aging from preclinical AD prior to clinical symptom manifestation. Cerebral perfusion, as measured by arterial spin labeling magnetic resonance imaging (ASL-MRI), has been shown to distinguish between normal controls and adults with AD. In addition to demonstrating diagnostic utility, CBF has shown usefulness as a tool for identifying those who are at risk for AD and for predicting subtle cognitive decline and conversion to mild cognitive impairment and AD. Taken together, this evidence not only implicates CBF as a useful biomarker for tracking disease severity and progression, but also suggests that ASL-measured CBF may be useful for identifying candidates for future AD treatment trials, especially in the preclinical, asymptomatic phases of the disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10571-015-0261-z

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 122 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Hays, C. C., Zlatar, Z. Z., & Wierenga, C. E.
Affiliations
  • San Diego State University (US)
  • University of California San Diego (US)
Corresponding author
Wierenga, Christina E.
Venue
Cellular and Molecular Neurobiology
Published
2016-02-22
Volume
36
Issue
2
Pages
167-179
ISSN
  • 0272-4340 (ISSN-L)
  • 1573-6830
OpenAlex
W2283957277
Cited by
213
References
122
Citations by year
2026: 8 · 2025: 18 · 2024: 18 · 2023: 24 · 2022: 25 · 2021: 27 · 2020: 19 · 2019: 25 · 2018: 24 · 2017: 19 · 2016: 5
Type
book review
Language
en
Open access
Locations
  • Cellular and Molecular Neurobiology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • VA CSR&D Merit Award (5I01CX000565)
  • National Institutes of Health T32 (MH019934)
  • National Science Foundation Graduate Research Fellowship Program (2015207525)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
Keywords
cerebral blood flow, preclinical Alzheimer's disease, arterial spin labeling, cerebral perfusion, biomarkers, normal aging, mild cognitive impairment, cognitive decline prediction, disease progression
MeSH terms
Aging, Alzheimer Disease, Cerebrovascular Circulation, Humans, Risk Factors, Biomarkers, Genetic Predisposition to Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review